Sunshine Biopharma Files 8-K on Financials
Ticker: SBFMW · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Sunshine Biopharma dropped an 8-K on April 1st detailing their financials. Check it out.
AI Summary
On April 1, 2024, Sunshine Biopharma, Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Mountain West Business Solutions, Inc., is incorporated in Colorado and its fiscal year ends on December 31st.
Why It Matters
This 8-K filing provides an update on Sunshine Biopharma's financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- Mountain West Business Solutions, Inc. (company) — Former company name
- April 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Sunshine Biopharma, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 1, 2024.
What was Sunshine Biopharma, Inc. formerly known as?
Sunshine Biopharma, Inc. was formerly known as Mountain West Business Solutions, Inc.
In which state is Sunshine Biopharma, Inc. incorporated?
Sunshine Biopharma, Inc. is incorporated in Colorado.
What is the business address listed for Sunshine Biopharma, Inc.?
The business address listed for Sunshine Biopharma, Inc. is 1177 Avenue of the Americas, 5th Floor, New York, NY 10036.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-01 14:26:22
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 27KB
- sunshine_ex9901.htm (EX-99.1) — 16KB
- image_001.gif (GRAPHIC) — 3KB
- 0001683168-24-001993.txt ( ) — 264KB
- sbfm-20240401.xsd (EX-101.SCH) — 3KB
- sbfm-20240401_def.xml (EX-101.DEF) — 26KB
- sbfm-20240401_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240401_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
02 Results of Operations
Item 2.02 Results of Operations and Financial Condition. On April 1, 2024, Sunshine Biopharma, Inc. (the "Company") issued a press release announcing the Company's financial results for the period ended December 31, 2023. The press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (formatted in Inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 1, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3